The relationship between clinical response and plasma neuroleptic levels in schizophrenia is unclear. A part from the inadequacy of the plasma neuroleptic assay method, resistance to neuroleptic treatment in some schizophrenics presents a serious problem in studies looking into the plasma drug level versus clinical response correlation. Previous studies have suggested a very wide range of plasma neuroleptic levels in responders. At present, plasma neuroleptic level does not predict clinical response in schizophrenics in general, but may have application in special situations such as suspected drug toxicity, neuroleptic resistance or idiosyncratic response to neuroleptic drugs.
References
1.
LindenR., DavisJ.M., RubensteinJ.Antipsychotics in the maintenance treatment of schizophrenia. In: StancerH.C., GarfinkelP., RakoffV., eds. Guidelines for the use of psychoactive drugs.New York: Spectrum Publications, 1984.
ClarkM.L., RamseyH.R., RahhalD.L.. Chlorpromazine in chronic schizophrenia: the effect of age and hospitalization on behavioral dose-response relationships.Arch Gen Psychiatry1972; 27: 479–483.
4.
PrienR.F., ColeJ.O.High dose chlorpromazine therapy in chronic schizophrenia. Report of national institute of mental health psychopharmacology research branch collaborative study group.Arch Gen Psychiatry1968; 18: 482–495.
5.
CurryS.H., MarshallH.J.L., DavisJ.M., JanowskyD.Chlorpromazine plasma levels and effects.Arch Gen Psychiatry1970; 22: 289–296.
6.
Rivera-CalimlimL., NasrallahH., StraussJ., LasagnaL.Clinical response and plasma levels: effect of dose, dosage schedule, and drug interactions on plasma chlorpromazine levels.Am J Psychiatry1976; 133: 646–652.
7.
GarverD.L., DekirmenjianH., DavisJ.M.. Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine.Am J Psychiatry1977; 134: 304–307.
8.
CalilH.M., AveryD.H., HolisterL.E.. Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations.Psychiatry Res1979; 1: 39–44.
9.
BjorndalN., BjerreM., GerlachJ.. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol and serum prolactin.Psychopharmacology1980; 67: 17–23.
10.
TuneL.E., CreeseI., DePauloJ.R.. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.Am J Psychiatry1980; 137: 187–190.
11.
MagliozziJ.R., HollisterL.E., ArnoldK.V., EarleG.M.Relationship of serum haloperidol levels to clinical response in schizophrenic patients.Am J Psychiatry1981; 138: 365–367.
12.
MayP.R.A., van PuttenT., JendenD.J.. Chlorpromazine levels and the outcome of treatment in schizophrenic patients.Arch Gen Psychiatry1981; 38: 202–207.
13.
Van PuttenT., MayP.R.A., JendenD.J.Does a plasma level of chlorpromazine help?Psychol Med1981; 11: 729–734.
14.
HaasS., BeckmannH.Pimozide versus haloperidol in acute schizophrenia — a double-blind controlled study.Pharmacopsychiatrica1982; 15: 70–74.
TangS.W., GlaisterJ., DavidsonL.. Total and free plasma neuroleptic levels in schizophrenic patients.Psychiatry Res1984 (in press).
17.
Wode-HelgodtB., BorgS., FyroB., SedvallG.Clinical effects and drug concentrations in plasma and cerebral spinal fluid in psychotic patients treated with fixed doses of chlorpromazine.Acta Psychiatr Scand1978; 58: 149–173.
